vaccines_the week in review_5 january 2013

7/30/2019 Vaccines_The Week in Review_5 January 2013

1/28

This weekly summary targets news, events, announcements, articles and research in the global vaccine ethics andpolicy space and is aggregated from key governmental, NGO, international organization and industry sources, keypeer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes andissues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in itscoverage. Vaccines: The Week in Review is also posted in pdf form and as a set of blog posts athttp://centerforvaccineethicsandpolicy.wordpress.com/. This blog allows full-text searching of over 3,500 entries.

Comments and suggestions should be directed to

David R. Curry, MSEditor andExecutive DirectorCenter for Vaccine Ethics & Policy

[email protected]

- A pdf version of this issue is available on our blog:http://centerforvaccineethicsandpolicy.wordpress.com/

Global Polio Eradication Initiativehttp://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx[Editors Extract and bolded text]

In the first outbreak of polio in 2012 outside of an endemic country or acountry with re-established poliovirus, Niger has reported a case of wild poliovirus. This is thefirst case in the country since December 2011 and is related to virus originating in Nigeria.- 2012 ends with fewest wild polio cases ever: The year ended with the fewest childrenparalyzed by wild polio virus, in the fewest places, in history. Two hundred and eighteen wildpolio cases have been reported so far for 2012 a greater than 60% reduction from 2011. Overthe year, through the tireless dedication of the on-the-ground heroes of polio eradication, more

than 2 billion doses of vaccine were distributed to 429 million children around the world.

- One new WPV case was reported in the past week (1 WPV1 from the Federal CapitalTerritory), bringing the total number of WPV cases for 2012 to 119. This is the most recent inthe country and had onset of paralysis on 3 December. The area was covered in Sub-nationalImmunization Days on 18-21 December.
http://centerforvaccineethicsandpolicy.wordpress.com/mailto:[email protected]://centerforvaccineethicsandpolicy.wordpress.com/http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspxmailto:[email protected]://centerforvaccineethicsandpolicy.wordpress.com/http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspxhttp://centerforvaccineethicsandpolicy.wordpress.com/


2/28

- No new circulating vaccine-derived poliovirus cases (cVDPV) were reported in the past week. -The total number of cVDPV cases for 2012 remains 4, with the most recent having onset ofparalysis on 16 August.- Given spread of WPV of Nigerian origin to Niger, targeted Supplementary Immunization

Activities will take place in high-risk and under-served districts in Nigeria on 12-15 January,synchronized with Niger. National Immunization Days across Nigeria are planned for 2-5February and 2-5 March.

- One new WPV case was reported in the past week, a WPV1 with onset of paralysis on 30November in Khyber Pakhtunkhwa. The total number of WPV cases for 2012 is 58.- Three new circulating vaccine-derived poliovirus (cVDPV) cases were reported in the pastweek, two from Balochistan and one from Sindh (Karachi area). The most recently reportedcase occurred in Sindh on 8 December and is related to the Balochistan outbreak. The totalnumber of cVDPV cases for 2012 is now 15.

- Niger reports polio: In the first outbreak of polio in 2012 outside of an endemic country or acountry with re-established poliovirus, Niger has reported a case of wild poliovirus. This is thefirst case in the country since December 2011 and is related to virus originating in Nigeria.

- One new WPV case was reported in the past week, a WPV1 from Tahoua province in Nigerwith onset of paralysis on 15 November. This is the first case in the region in 2012.

[Editors Note: Please see an associated editorial in The Lancet inJournal Watch below.]

noting that the work of the Decade of Vaccines is continuing carried out by the stakeholders that developed the GVAP. The original plan was for the DoVCollaboration, including the secretariat, to dissolve or sunset at the end of 2012 so as not tocreate an additional structure. The countries, the regions and global health organizations willcontinue to carry out the vision of the GVAP at the country, regional and global levels.http://www.dovcollaboration.org/dov-collaboration-updates/december-2012-news-report/

The , vol. 88, 1 (pp 116)includes: Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012

conclusions and recommendations

http://www.who.int/entity/wer/2013/wer8801.pdf[Editors Note: Below is an excerpt for the WER summary of the meetings GVAP agenda item]

The session included an overview of progress in putting the GVAP into operation since the65th World Health Assembly (WHA) in May 2012. Discussions have begun at the Regional levelto update regional immunization plans in alignment with GVAP and to establish processes tomonitor and report progress to the respective Regional Committees each year. The WHO and
http://www.dovcollaboration.org/dov-collaboration-updates/december-2012-news-report/http://www.who.int/entity/wer/2013/wer8801.pdfhttp://www.dovcollaboration.org/dov-collaboration-updates/december-2012-news-report/http://www.who.int/entity/wer/2013/wer8801.pdf


3/28

UNICEF guidance for preparation of national multi-year and annual plans for immunization arebeing updated to align them with the guiding principles and strategic objectives of GVAP and tofoster greater alignment with national health sector plans.

The proposed structure and process for monitoring the implementation of the GVAP througha Monitoring & Evaluation /Accountability Framework was described. The framework has 3elements: (i) monitoring results (based on the indicators for the GVAP Goals and StrategicObjectives); (ii) monitoring commitments and resources; and (iii) an independent review ofprogress.

Progress was described in the efforts to finalize monitoring indicators, establish operationaldefinitions, sources of data, and the reporting process. SAGE was presented with the changesmade to the indicators since its April 2012 meeting and the rationale for doing so, and wasspecifically asked for comments and recommendations.

SAGE discussions mainly focused on:(1) the feasibility and need for surveys to validate district level vaccine coverage measures; (2)adding an indicator of DTP3 coverage 80% for 3 years; (3) proposed indicators to measure

confidence in immunization; (4) retention of indicator on district level DTP3 coverage; (5)choice of drop-out rate between the first dose of DTP and first dose of measles containing

vaccine (MCV1) (DTP1-MCV1), or between the first and third dose of DTP vaccine (DTP1-DTP3); (6) addition of a surveillance indicator; (7) addition of an indicator to measureintegration of immunization within health systems; and (8) addition of a vaccine priceindicator

at its 132nd session[EB132] in Geneva, 2129 January 2013. The agenda item is listed as:9. Communicable diseases9.1 Global vaccine action plan

The supporting document - EB132/18 is not yet posted.http://apps.who.int/gb/ebwha/pdf_files/EB132/B132_1-en.pdf

, noting that

the disparity between the amounts Low Income and Middle Income Countries pay for the samevaccine can be significant. Shanelle Hall, Director of UNICEFs Supply Division, said, Thecurrent market prices of new vaccines put these products out of reach for many countrieswhose economies have transitioned from Low to 'Middle Income over the last 20 years. Thistender highlights work with the UN World Health Organization, industry, governments andpartners to establish affordable, sustainable price levels for countries that are not eligible forinternational financial support to introduce these new and important life-saving vaccines."

UNICEF said that for countries that wish to continue to purchase on their own, this tenderwill improve pricing transparency by publishing reference price levels, product profiles andcharacteristics. This information will serve as the basis for negotiations between interestedgovernments and manufacturers. The final price would be independently contracted. Ms. Halladded that, Making sure that children in Middle Income Countries have access to a newgeneration of life-saving supplies is critical. This tender builds on industry's commitment toimproved access and sustainable pricing consistent with the tenets of tiered pricing. Our goal is
http://apps.who.int/gb/ebwha/pdf_files/EB132/B132_1-en.pdfhttp://apps.who.int/gb/ebwha/pdf_files/EB132/B132_1-en.pdf


4/28

to help catalyse a more efficient and healthy market, which combined with increasing countrycommitment, will serve children in the decades to come, she added.

The World Bank classifies a Middle Income Country as a country with a per capita GrossNational Income between US$1,026 and US$12,475. Today, Middle Income Countries are hometo 75 per cent of the worlds poor who live on less than US$2 a day. Middle Incomegovernments that have so far expressed an indicative interest in the outcome of this tenderinclude: Albania, Botswana, Cape Verde, Egypt, Gabon, Jordan, Lebanon, Moldova, Morocco,Namibia, the State of Palestine, the Philippines, Sri Lanka, Swaziland, Syria, Tunisia andTurkmenistan. UNICEF is awaiting manufacturers' responses and expects to begin issuingpurchase orders on behalf of subscribing countries as early as June 2013. The Request forProposal RFP-DAN-2012-501580 for Pneumococcal, Rotavirus and Human Papillomavirus

Vaccines is available here: http://www.unicef.org/supply/index_66941.html. UNICEFs strategyfor vaccine procurement in Middle Income Countries is presented here:http://www.unicef.org/supply/index_66348.htmlhttp://www.unicef.org/media/media_67112.html

, findingthat UNICEF had shown it was able to strengthen its effectiveness and to coordinate efforts toaddress key issues. The latest assessment of UNICEF was led by the governments of Austriaand Spain MOPAN assessments provide an important snapshot of an organizationsmanagement effectiveness from a strategic, operational, relationship and knowledge-basedperspective. The assessment relies largely on perception-based surveys of in-country partners,peer organizations and donors. In 2012, country-level surveys were undertaken in Cambodia,the Democratic Republic of the Congo, Ghana, Honduras, Morocco, Niger, Nigeria, Philippinesand Zimbabwe, serving as the basis of the 2012 report. UNICEF said it welcomes the commonMOPAN approach and the consultative process and is committed to follow up on therecommendations.31 December 2012 http://www.unicef.org/media/media_67100.htmlFull MOPAN Reports on UNICEF:http://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdf

The Delivering Oral Vaccine Effectively (DOVE) programwill provide relief agencies and governments with technical assistance on how to use oralcholera vaccine, evaluate current vaccine-use practices and develop new field surveillancemethods for monitoring and controlling outbreaks of the disease. David Sack, MD, director ofDOVE and professor in the Department of International Health at the Bloomberg School, said,

We believe this grant will greatly facilitate the appropriate use of the new cholera vaccine. Inpartnership with the World Health Organization, UNICEF and other national and internationalagencies, we believe the DOVE project will provide the knowledge, technical assistance and
http://www.unicef.org/supply/index_66941.htmlhttp://www.unicef.org/supply/index_66348.htmlhttp://www.unicef.org/media/media_67112.htmlhttp://www.unicef.org/media/media_67100.htmlhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdfhttp://www.unicef.org/supply/index_66941.htmlhttp://www.unicef.org/supply/index_66348.htmlhttp://www.unicef.org/media/media_67112.htmlhttp://www.unicef.org/media/media_67100.htmlhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdfhttp://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdf


5/28

encouragement to bring this life-saving vaccine to those who need it most. In addition toresearching and evaluating vaccine-use practices, DOVE will establish cholera surveillance inthe northern region of Cameroon near Lake Chad, which appears to be a cholera hotspot. Thesite will help researchers develop and study methods for detecting outbreaks in remote areasand potentially for using oral vaccine to contain the disease.http://www.eurekalert.org/pub_releases/2012-12/jhub-jhr122712.php

December 2012Key public health milestones were reached in 2012, including the end of polio transmission in

India and meeting the Millennium Development Goal target on drinking water ahead ofschedule. Governments made important decisions on combating illicit trade in tobacco products,monitoring noncommunicable diseases, and conducting research on H5N1 influenza.WHO supported response to a number of disease outbreaks, including Ebola in Uganda. TheOrganization encouraged countries to invest in testing, treating and tracking all cases of

malaria, and to improve access to contraceptives. It issued guidance on the use of antiretroviraldrugs to both prevent HIV transmission and keep people healthy.

WHO published new statistics highlighting the growing problem of high blood pressure anddiabetes, (and) that 15 million babies are born preterm every year, but that overall progress onchild survival is speeding up.

Other recommendations showed how to use weather information to protect public health, andhow to ensure people with mental health conditions receive good care. World Health Dayoutlined ways to ensure healthy ageing, and the World Health Assembly adopted decisions onissues including nutrition, adolescent pregnancy, and the reform of WHO.http://www.who.int/features/2012/year_review/en/index.html

Vaccines: The Week in Review has expanded its coverage of new reports, books, research andanalysis published independent of the journal channel covered in Journal Watch below. Ourinterests span immunization and vaccines, as well as global public health, health governance,and associated themes. If you would like to suggest content to be included in this service,please contact David Curry at:[email protected]

No new content.

Vaccines: The Week in Reviewcontinues its weekly scanning of key peer-reviewed journals toidentify and cite articles, commentary and editorials, books reviews and other contentsupporting our focus on vaccine ethics and policy.

Weselectively provide full text of some editorial and comment articles that are specifically relevant
http://www.eurekalert.org/pub_releases/2012-12/jhub-jhr122712.phphttp://www.who.int/features/2012/year_review/en/index.htmlmailto:[email protected]://www.eurekalert.org/pub_releases/2012-12/jhub-jhr122712.phphttp://www.who.int/features/2012/year_review/en/index.htmlmailto:[email protected]


6/28

to our work. Successful access to some of the links provided may require subscription or otheraccess arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact DavidCurry at:[email protected]

Volume 103, Issue 1 (January 2013)http://ajph.aphapublications.org/toc/ajph/current[Reviewed earlier]

1 January 2013, Vol. 158. No. 1http://www.annals.org/content/current

Noah McKittrick, MD; Ian Frank, MD; Jeffrey M. Jacobson, MD; C. Jo White, MD; Deborah Kim,RPh; Rosemarie Kappes, RN, MPH; Carol DiGiorgio, RN; Thomas Kenney, BS; Jean Boyer, PhD;Pablo Tebas, MD; and for the Center for AIDS ResearchAbstractBackground: HIV-infected persons have less robust antibody responses to influenza vaccines.Objective: To compare the immunogenicity of high-dose influenza vaccine with that of standarddosing in HIV-positive participants.Design: Randomized, double-blind, controlled trial. (ClinicalTrials.gov: NCT01262846)Setting: The MacGregor Clinic of the Hospital of the University of Pennsylvania, Philadelphia,from 27 October 2010 to 27 March 2011.Participants: HIV-infected persons older than 18 years.Intervention: Participants were randomly assigned to receive either a standard dose (15 mcg of

antigen per strain) or a high dose (60 mcg/strain) of the influenza trivalent vaccine.Measurements: The primary end point was the rate of seroprotection, defined as antibody titersof 1:40 or greater on the hemagglutination inhibition assay 21 to 28 days after vaccination. Theprimary safety end point was frequency and intensity of adverse events. Secondary end pointswere seroconversion rate (defined as a greater than 4-fold increase in antibody titers) and thegeometric mean antibody titer.Results: 195 participants enrolled, and 190 completed the study (93 in the standard-dose groupand 97 in the high-dose group). The seroprotection rates after vaccination were higher in thehigh-dose group for the H1N1 (96% vs. 87%; treatment difference, 9 percentage points [95%CI, 1 to 17 percentage points]; P = 0.029), H3N2 (96% vs. 92%; treatment difference, 3percentage points [CI, 3 to 10 percentage points]; P = 0.32), and influenza B (91% vs. 80%;

treatment difference, 11 percentage points [CI, 1 to 21 percentage points]; P = 0.030) strains.Both vaccines were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%)the most frequent adverse events.Limitations: The effectiveness of the vaccine in preventing clinical influenza was not evaluated.The number of participants with CD4 counts less than 0.200 109 cells/L was limited.Conclusion: HIV-infected persons reach higher levels of influenza seroprotection if vaccinatedwith the high-dose trivalent vaccine than with the standard-dose.
mailto:[email protected]://ajph.aphapublications.org/toc/ajph/currenthttp://www.annals.org/content/currentmailto:[email protected]://ajph.aphapublications.org/toc/ajph/currenthttp://www.annals.org/content/currenthttp://annals.org/article.aspx?articleid=1487780http://annals.org/article.aspx?articleid=1487780


7/28

Primary Funding Source: National Institute of Allergy and Infectious Diseases and Center forAIDS Research of the University of Pennsylvania.

(Accessed 5 January 2013)http://www.biomedcentral.com/bmcpublichealth/content

George M Ruhago, Frida N Ngalesoni, Ole F Norheim BMC Public Health 2012, 12:1119 (27December 2012)Abstract(provisional)BackgroundInequity in access to and use of child and maternal health interventions is impeding progresstowards the maternal and child health Millennium Development Goals. This study explores thepotential health gains and equity impact if a set of priority interventions for mothers and underfives were scaled up to reach national universal coverage targets for MDGs in Tanzania.

MethodsWe used the Lives Saved Tool (LiST) to estimate potential reductions in maternal and childmortality and the number of lives saved across wealth quintiles and between rural and urbansettings. High impact maternal and child health interventions were modelled for a five-yearscale up, by linking intervention coverage, effectiveness and cause of mortality using data fromTanzania. Concentration curves were drawn and the concentration index estimated to measurethe equity impact of the scale up.ResultsIn the poorest population quintiles in Tanzania, the lives of more than twice as many mothersand under-fives were likely to be saved, compared to the richest quintile. Scaling up coverageto equal levels across quintiles would reduce inequality in maternal and child mortality from apro rich concentration index of -0.11 (maternal) and -0.12 (children) to a more equitableconcentration index of -0,03 and -0.03 respectively. In rural areas, there would likely be aneight times greater reduction in maternal deaths than in urban areas and a five times greaterreduction in child deaths than in urban areas.ConclusionsScaling up priority maternal and child health interventions to equal levels would potentially savefar more lives in the poorest populations, and would accelerate equitable progress towardsmaternal and child health MDGs.The complete article is available as aprovisional PDF. The fully formatted PDF and HTML

versions are in production.

Volume 104 Issue 1 December 2012http://bmb.oxfordjournals.org/content/current[Reviewed earlier; No relevant content]

05 January 2013 (Vol 346, Issue 7889)
http://www.biomedcentral.com/bmcpublichealth/contenthttp://www.biomedcentral.com/content/pdf/1471-2458-12-1119.pdfhttp://bmb.oxfordjournals.org/content/currenthttp://www.biomedcentral.com/bmcpublichealth/contenthttp://www.biomedcentral.com/1471-2458/12/1119http://www.biomedcentral.com/1471-2458/12/1119http://www.biomedcentral.com/content/pdf/1471-2458-12-1119.pdfhttp://bmb.oxfordjournals.org/content/current


8/28

http://www.bmj.com/content/346/7889

BMJ 2013;345:e7594 (Published 28 December 2012)Abstract Open Access ArticleObjective To assess the risk of epileptic seizures in people with and without epilepsy aftervaccination with a monovalent AS03 adjuvanted pandemic A/H1N1 influenza vaccine(Pandemrix; Glaxo SmithKline, Sweden).Design Register based self controlled case series.Setting Three Swedish counties (source population 750 000).Participants 373 398 people (age 0-106, median 41.2) who were vaccinated. Vaccinated peoplewith epileptic seizures, diagnosed as inpatients or outpatients, at any time from 90 days beforeuntil 90 days after any dose of vaccine.Main outcome measures Endpoints were admission to hospital or outpatient hospital care withepileptic seizures as the main diagnosis. The effect estimate of relative incidence was calculatedas the incidence of epileptic seizures in period after exposure relative to the incidence of

epileptic seizures in two control periods, one before and one after vaccination.Results 859 people experienced epileptic seizures during the study period. There was noincreased risk of seizures in people with previously diagnosed epilepsy (relative incidence 1.01,95% confidence interval 0.74 to 1.39) and a non-significant decrease in risk for people withoutepilepsy (0.67, 0.27 to 1.65) during the day 1-7 risk period (where day 1 is the day ofvaccination). In a second risk period (day 8-30), there was a non-significant increased risk ofseizures in people without epilepsy (1.11, 0.73 to 1.70) but no increase in risk for those withepilepsy (1.00, 0.83 to 1.21).Conclusions This study found no evidence of an increase in risk of presentation to hospital withepileptic seizures after vaccination with a monovalent AS03 adjuvanted pandemic H1N1influenza vaccine.

Volume 91, Number 1, January 2013, 1-80http://www.who.int/bulletin/volumes/90/12/en/index.html

Gorik Ooms, Claire Brolan, Natalie Eggermont, Asbjrn Eide, Walter Flores, Lisa Forman, Eric AFriedman, Thomas Gebauer, Lawrence O Gostin, Peter S Hill, Sameera Hussain, Martin McKee,Moses Mulumba, Faraz Siddiqui, Devi Sridhar, Luc Van Leemput, Attiya Waris & Albrecht Jahndoi: 10.2471/BLT.12.115808Bulletin of the World Health Organization 2013;91:2-2A. doi: 10.2471/BLT.12.115808

European Commissioner for Development Andris Piebalgs recently pointed out the need forupdated and modernised [Millennium Development Goals], providing decent living standardsfor all a set of minimum floors below which no one should fall.1 He added that these MDGsplus would provide the basic rights that every citizen on the planet should expect with,where necessary, for the poorest countries, the support of the international community throughcontinued overseas development assistance.1

We concur with Commissioner Piebalgs demand for basic rights for all people and feel thatthe right to health and its imperative of narrowing health inequities should be central to the
http://www.bmj.com/content/346/7889http://www.who.int/bulletin/volumes/90/12/en/index.htmlhttp://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R1http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R1http://www.bmj.com/content/346/7889http://www.bmj.com/content/345/bmj.e7594http://www.bmj.com/content/345/bmj.e7594http://www.bmj.com/content/345/bmj.e7594http://www.who.int/bulletin/volumes/90/12/en/index.htmlhttp://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R1http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R1


9/28

post-2015 international health agenda. We take this stand as members of Go4Health, aconsortium of academics and members of civil society tasked with advising the EuropeanCommission on the international health-related goals to follow the Millennium DevelopmentGoals (MDGs). What does this mean, given that the present MDGs on maternal health, childhealth and infectious disease control will probably be succeeded by the goal of universal healthcoverage, defined by the World Health Organization (WHO) as universal coverage with neededhealth services and financial risk protection?2,3

First, we view an aggregate health goal such as universal health coverage as an improvementover the current set of disparate goals. Ensuring the right to health requires a comprehensiveapproach. Universal health coverage anchored in the right to health, while building on efforts tomeet the present health-related MDGs, would raise the bar for improving health care overall.

Second, although we support making universal health care one of the post-2015 developmentgoals, we feel that universal health coverage is not enough, as defined by WHO and typicallyconceived,3 to ensure the right to health. For the right to health to become a reality, policy-makers must strive for a healthy physical and social environment (e.g. safe drinking water andgood sanitation, adequate nutrition and housing, safe and healthy occupational andenvironmental conditions and gender equality.)4 These underlying determinants of health are

partially captured in the present MDGs and their corresponding targets, although underdifferent goals (e.g. nutrition under MDG 1, to eradicate extreme hunger and poverty, andwater and sanitation under MDG 7, to promote environmental sustainability). Thesedeterminants and many more that are needed for a sustainable healthy environment shouldfigure prominently in the post-2015 health agenda.

Third, specifying peoples entitlements is necessary but not enough. One important reason forthe failure to attain all MDGs is the ambiguity of the shared responsibility mentioned in

Article 2 of the Millennium Declaration: We recognize that, in addition to our separateresponsibilities to our individual societies, we have a collective responsibility to uphold theprinciples of human dignity, equality and equity at the global level.5 If we want every citizenon the planet to claim his or her right to health, the post-2015 health agenda must specify howcitizens will participate in the decision-making processes surrounding their health services andtheir physical and social environment. Furthermore, the agenda should also explicitly describethe accountability mechanisms that will make it possible for people to claim not beg for additional national public resources and international assistance, if needed.

Finally, we are concerned not just about the substance of the post-2015 health goals, butalso about the process of formulating them. We have entered a post-2015 frenzy, as evidencedby the appointment of a high-level panel expected to submit a report to the United NationsSecretary-General in the first half of 2013.6 Go4Health is committed to ensuring that any post-2015 health development goals are articulated in collaboration with the communities whosehealth is at stake. However, truly participatory consultations take time and require a continuingrelationship among researchers, governments and those communities. Such an approach shouldbe adopted to prevent goals from being formulated by policy elites after token and superficial

consultations, which would be at odds with the rights that must underpin the new goals.References- Piebalgs A. Achieving the MDGs and looking to the future. Luxembourg: EuropeanCommission; 2012. Available from: http://europa.eu/rapid/press-release_SPEECH-12-707_en.htm [accessed 30 November 2012].- Evans DB, Marten R, Etienne C. Universal health coverage is a development issue. Lancet2012; 380: 864-5 doi: 10.1016/S0140-6736(12)61483-4 pmid: 22959373.
http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R2http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R3http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R3http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R4http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R5http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R6http://europa.eu/rapid/press-release_SPEECH-12-707_en.htmhttp://europa.eu/rapid/press-release_SPEECH-12-707_en.htmhttp://dx.doi.org/10.1016/S0140-6736(12)61483-4http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=22959373&dopt=Abstracthttp://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R2http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R3http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R3http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R4http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R5http://www.who.int/bulletin/volumes/91/1/12-115808/en/index.html#R6http://europa.eu/rapid/press-release_SPEECH-12-707_en.htmhttp://europa.eu/rapid/press-release_SPEECH-12-707_en.htmhttp://dx.doi.org/10.1016/S0140-6736(12)61483-4http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=22959373&dopt=Abstract


10/28

- World Health Organization [Internet]. Positioning health in the post-2015 developmentagenda. Geneva: WHO; 2012. Available from:http://www.who.int/topics/millennium_development_goals/post2015/en/ [accessed 30November 2012].- General Comment No. 14. The right to the highest attainable standard of health. In: Twenty-second session, Committee on Economic, Social and Cultural Rights, Geneva, 25 April12 May2000 [Internet]. Geneva: CESCR; 2000 (E/C.12/2000/4). Available from:http://www2.ohchr.org/english/bodies/cescr/ [accessed 30 November 2012].- Resolution 55/2. United Nations Millennium Declaration. In: Fifty-fifth United Nations General

Assembly, New York, 58 September 2000 [Internet]. New York: United Nations; 2000(A/RES/55/2). Available from: https://www.un.org/ga/55/ [accessed 30 November 2012].- United Nations Secretary-General [Internet]. Secretary-General assembles high-level panel onpost-2015 development agenda: appointing 26 members of government, civil society, privatesector (press release). New York: Department of Public Information, News and Media Division;31 July 2012. Available from: http://www.un.org/News/Press/docs/2012/sga1364.doc.htm[accessed 30 November 2012].

Osman David Mansoor, Debra Kristensen, Andrew Meek, Simona Zipursky, Olga Popovaa,InderJit Sharma, Gisele Miranda, Jules Millogo & Heidi Lasherdoi: 10.2471/BLT.12.110700

ConclusionThe VPPAG is an important forum where stakeholders from the vaccine industry and

immunization programmes interact to discuss in depth vaccine product characteristics and theirimpact on immunization programmes. Already, the VPPAG has brought about meaningfulchanges in the way vaccines are packaged and presented for developing country programmes.(The groups 2008 terms of reference,18 current gPPP24 and a profile previously completed forthe pneumococcal vaccine19 are available for download on WHOs web site.)

The VPPAG could provide a model for organizations struggling to meet the needs of marketsin both high- and low-income countries. Such organizations would benefit from feedback onproduct characteristics that could improve product applicability in markets with differentinfrastructures, and consumers in developing countries could benefit from access to a widerarray of suitable products without unnecessary delay. Having a forum that allows constructivedialogue between the public and private sector furthers our shared goal of preventing disease,disability and death from vaccine-preventable diseases by designing products that can moreeasily reach those who will most benefit from immunization.

(Accessed 5 January 2013)http://www.resource-allocation.com/[No new relevant content]

Volume 19, Number 1January 2013http://www.cdc.gov/ncidod/EID/index.htm
http://www.who.int/topics/millennium_development_goals/post2015/en/http://www2.ohchr.org/english/bodies/cescr/https://www.un.org/ga/55/http://www.un.org/News/Press/docs/2012/sga1364.doc.htmhttp://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R18http://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R24http://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R19http://www.resource-allocation.com/http://www.cdc.gov/ncidod/EID/index.htmhttp://www.who.int/topics/millennium_development_goals/post2015/en/http://www2.ohchr.org/english/bodies/cescr/https://www.un.org/ga/55/http://www.un.org/News/Press/docs/2012/sga1364.doc.htmhttp://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R18http://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R24http://www.who.int/bulletin/volumes/91/1/12-110700/en/index.html#R19http://www.resource-allocation.com/http://www.cdc.gov/ncidod/EID/index.htm


11/28

[Reviewed earlier]

Volume 18, Issue 1, 03 January 2013http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678[No relevant content]

Volume VI, Issue 1: Fall 2012 December 31, 2012http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/

Timothy K. Mackey and Thomas E. NovotnyAbstract

Global health governance is widely considered fragmented after more than a decade ofinconsistent support for multi-lateral organizations and faced with the emergence of many newglobal health donors and non-state enterprises. This paper addresses a series of events markedby enactment of the Helms-Biden agreement in 1999. This legislation ensured that UnitedStates funding for the United Nations was to be conditional upon reforms and reductions of U.S.assessments. Although passage of the legislation allowed its largest contributor/debtor to payback arrears and continue payments going forward, it also represented a growing trend in U.S.unilateralism and disengagement from support for multi-national organizations. In particular,continued arrears and budgetary restrictions have affected specialized U.N. agencies such asthe World Health Organization. This agency has experienced a zero nominal growth budget thatmay have impacted its governance capacity. We review the potential impact of the Helms-Bidenlegislation on WHO governance, and suggest that the governance of this important globalhealth agency may benefit from its timely repeal.

Lisa Forman, Donald C. Cole, Gorik Ooms, and Merrick ZwarensteinAbstractGlobal health funding has experienced dramatic growth over the past decades, rising tounprecedented levels through the 2000s. Since the onset of the 2008 global recession, fundinggrowth has significantly slowed down and in some cases regressed. In this paper we argue thatthe right to health and a rights-based approach to health may offer important norms, strategiesand tools to sustain, supplement, and advance global health funding and to thereby mitigatepersisting inter- and intra-country health inequities. This paper interrogates this thesis through

the legal framework of the right to health, the theoretical perspective of social constructivism,and practical strategies where human rights have contributed towards progressive healthoutcomes within countries and in global fora. While many new institutional global healthfunders are non-state actors and therefore weakly bound under international human rights law,the predominant source of funding still comes from states, which are the primary human rightsduty-bearers under international law. Accordingly, we argue that states hold internationalresponsibilities to cooperate and assist in realizing the right to health in low and middle incomecountries (LMICs) and that this duty extends to providing international assistance for health. We
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/http://blogs.shu.edu/ghg/files/2012/12/GHGJ-VOLUME-VI-ISSUE-1-FALL-2012-Improving-United-Nations-Funding-to-Strengthen-Global-Health-Governance-Amending-the-Helms-%E2%80%93-Biden-Agreement.pdfhttp://blogs.shu.edu/ghg/files/2012/12/GHGJ-VOLUME-VI-ISSUE-1-FALL-2012-Improving-United-Nations-Funding-to-Strengthen-Global-Health-Governance-Amending-the-Helms-%E2%80%93-Biden-Agreement.pdfhttp://blogs.shu.edu/ghg/files/2012/12/VOLUME-VI-ISSUE-1-FALL-2012-Human-Rights-and-Global-Health-Funding-What-Contribution-Can-the-Right-to-Health-Make-to-Sustaining-and-Extending-International-Assistance-for-Health_-.pdfhttp://blogs.shu.edu/ghg/files/2012/12/VOLUME-VI-ISSUE-1-FALL-2012-Human-Rights-and-Global-Health-Funding-What-Contribution-Can-the-Right-to-Health-Make-to-Sustaining-and-Extending-International-Assistance-for-Health_-.pdf


12/28

set out five paths by which use of the human right to health might directly and indirectlyadvance funding for health and health services at the domestic and global levels: includingrights-based litigation, rights-based social advocacy, development of the ethical content of theright to health, use of rights-based approaches to monitor and promote the right to health, anddeveloping a new legal paradigm of funding essential health services globally. We conclude thathuman rights and the right to health can offer important tools to health policy-makers and civilsociety actors alike to address inadequate resource allocations to health at various levels.

[Accessed 5 January 2013]http://www.globalizationandhealth.com/[No new relevant content]

December 2012; Volume 31, Issue 12

http://content.healthaffairs.org/content/current

[No specific relevant content on vaccines/immunization]

Vol 14, No 2 (2012)http://hhrjournal.org/index.php/hhr[Reviewed earlier]

Volume7 / Issue04 / October 2012, pp 383 - 384http://journals.cambridge.org/action/displayIssue?jid=HEP&tab=currentissue

[Reviewed earlier; No specific relevant content on vaccines/immunization]

Volume 27 Issue 8 December 2012http://heapol.oxfordjournals.org/content/current[Reviewed earlier]

(formerly Human Vaccines)Volume 9, Issue 1 January 2013http://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/1/

Maciej L. Goniewicz and Marcin Delijewskihttp://dx.doi.org/10.4161/hv.22060
http://www.globalizationandhealth.com/http://content.healthaffairs.org/content/currenthttp://hhrjournal.org/index.php/hhrhttp://journals.cambridge.org/action/displayIssue?jid=HEP&tab=currentissuehttp://heapol.oxfordjournals.org/content/currenthttp://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/1/http://dx.doi.org/10.4161/hv.22060http://www.globalizationandhealth.com/http://content.healthaffairs.org/content/currenthttp://hhrjournal.org/index.php/hhrhttp://journals.cambridge.org/action/displayIssue?jid=HEP&tab=currentissuehttp://heapol.oxfordjournals.org/content/currenthttp://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/1/http://www.landesbioscience.com/journals/vaccines/article/22060/http://dx.doi.org/10.4161/hv.22060


13/28

Abstract:Tobacco smoking is globally far more widespread than use of any other substance of abuse.Nicotine is an important tobacco constituent that is responsible for addictive properties ofsmoking. The currently available medications for the treatment of nicotine addiction havelimited efficacy. A challenging novel therapeutic concept is vaccination against nicotine. Anefficient vaccine would generate antibodies that sequester nicotine in the blood and prevent itsaccess to the brain. The vaccine would have great potential for treating nicotine addiction andfor relapse prevention. We reviewed the current status of vaccines against nicotine addictionthat are undergoing clinical trials or are in preclinical development. We discuss problemsassociated with the development of nicotine vaccines, their efficacy in addiction treatment,challenges and ethical concerns. Existing evidence indicates that nicotine vaccination is welltolerated and capable of inducing an immune response but its effectiveness in increasingsmoking abstinence has not been shown so far.

Qiang Chen and Huafang Laihttp://dx.doi.org/10.4161/hv.22218

Abstract:Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that mimicthe native architecture of viruses but lack the viral genome. VLPs have emerged as a premiervaccine platform due to their advantages in safety, immunogenicity, and manufacturing. Theparticulate nature and high-density presentation of viral structure proteins on their surface alsorender VLPs as attractive carriers for displaying foreign epitopes. Consequently, several VLP-based vaccines have been licensed for human use and achieved significant clinical andeconomical success. The major challenge, however, is to develop novel production platformsthat can deliver VLP-based vaccines while significantly reducing production times and costs.Therefore, this review focuses on the essential role of plants as a novel, speedy and economicalproduction platform for VLP-based vaccines. The advantages of plant expression systems arediscussed in light of their distinctive posttranslational modifications, cost-effectiveness,production speed, and scalability. Recent achievements in the expression and assembly of VLPsand their chimeric derivatives in plant systems as well as their immunogenicity in animal modelsare presented. Results of human clinical trials demonstrating the safety and efficacy of plant-derived VLPs are also detailed. Moreover, the promising implications of the recent creation of

humanized glycosylation plant lines as well as the very recent approval of the first plant-madebiologics by the U. S. Food and Drug Administration (FDA) for plant production andcommercialization of VLP-based vaccines are discussed. It is speculated that the combinedpotential of plant expression systems and VLP technology will lead to the emergence ofsuccessful vaccines and novel applications of VLPs in the near future.

Petra Stcker, Manuel Dehnert, Melanie Schuster, Ole Wichmann and Yvonne Delerhttp://dx.doi.org/10.4161/hv.22192AbstractPurpose:Since March 2007, the Standing Committee on Vaccination (STIKO) recommends HPVvaccination for all 1217 y-old females in Germany. In the absence of an immunization register,
http://dx.doi.org/10.4161/hv.22218http://dx.doi.org/10.4161/hv.22192http://www.landesbioscience.com/journals/vaccines/article/22218/http://dx.doi.org/10.4161/hv.22218http://www.landesbioscience.com/journals/vaccines/article/22192/http://www.landesbioscience.com/journals/vaccines/article/22192/http://dx.doi.org/10.4161/hv.22192


14/28

we aimed at assessing HPV-vaccination coverage and knowledge among students in Berlin, thelargest city in Germany, to identify factors influencing HPV-vaccine uptake.Methods:Self-administered questionnaires were distributed to 10th grade school students in 14participating schools in Berlin to assess socio-demographic characteristics, knowledge, andstatements on vaccinations. Vaccination records were reviewed. Multivariable statisticalmethods were applied to identify independent predictors for HPV-vaccine uptake among femaleparticipants.Results:Between September and December 2010, 442 students completed the questionnaire (mean age15.1; range 1419). In total 281/442 (63.6%) students specified HPV correctly as a sexuallytransmitted infection. Of 238 participating girls, 161 (67.6%) provided their vaccination records.

Among these, 66 (41.0%) had received the recommended three HPV-vaccine doses. Reasonsfor being HPV-unvaccinated were reported by 65 girls: Dissuasion from parents (40.2%),dissuasion from their physician (18.5%), and concerns about side-effects (30.8%) (multiplechoices possible). The odds of being vaccinated increased with age (Odds Ratio (OR) 2.19, 95%Confidence Interval (CI) 1.16, 4.15) and decreased with negative attitude toward vaccinations

(OR = 0.33, 95%CI 0.13, 0.84).Conclusions:HPV-vaccine uptake was low among school girls in Berlin. Both, physicians and parents wereinfluential regarding their HPV-vaccination decision even though personal perceptions played animportant role as well. School programs could be beneficial to improve knowledge related toHPV.

Orna Baron-Epel, Batya Madjar, Rami Gerfat and Shmuel Rishponhttp://dx.doi.org/10.4161/hv.22503V and vaccines, and to offer low-barrier access to HPVvaccination.Abstract:Rates of vaccinations of healthcare workers with recommended vaccines are generally low inthe developed countries. Our goals were to identify attitudes associated with self-reportedvaccinations against pertussis and seasonal influenza among Israeli nurses in Mother and ChildHealthcare Centers (MCHC) in the Haifa District. Over 100 nurses answered a self-administeredquestionnaire. Forty two percent of the nurses reported receiving the pertussis vaccine in thelast five years and 44% reported receiving the influenza vaccine during the previous year.

Attitudes toward the importance of vaccinating nurses, trust in the public health authorities anddemand for autonomy were associated with receiving the pertussis vaccine. Attitudes towardthe importance of vaccinating nurses and trust were associated with receiving the influenzavaccine in a bivariant analysis. However, in the logistic regression models only attitudes toward

the importance of vaccinating nurses were associated with vaccinations [odds ratio (OR)- 3.66,95% confidence interval (CI)- 1.49.6 for pertussis and OR- 4.53, CI-1.613.0 for influenza].Jewish nurses reported more often receiving the influenza vaccine compared with the Arabnurses, whereas there was no difference between them in receiving the pertussis vaccine. Lowlevels of positive attitudes toward the importance of vaccinating nurses may inhibit nurses inMCHC from receiving vaccines. The demand for autonomy and low levels of trust may, in part,form these low levels of positive attitudes toward the importance of vaccinating nurses.
http://dx.doi.org/10.4161/hv.22503http://www.landesbioscience.com/journals/vaccines/article/22503/http://www.landesbioscience.com/journals/vaccines/article/22503/http://dx.doi.org/10.4161/hv.22503


15/28

2012, 1http://www.idpjournal.com/content[Accessed 5 January 2013][No new relevant content]

December 2012, Vol. 16, No. 12http://www.ijidonline.com/[Reviewed earlier]

http://jama.ama-assn.org/current.dtlJanuary 02, 2013, Vol 309, No. 1

[No relevant content]

December 26, 2012, Vol 308, No. 24[No relevant content]

Volume 26 issue 6 - Published: 2012http://www.emeraldinsight.com/journals.htm?issn=1477-7266&show=latest[Reviewed earlier; No relevant content]

Volume 207 Issue 3 February 1, 2013http://www.journals.uchicago.edu/toc/jid/current[No relevant content]

October-December 2012

Volume 4 | Issue 4Page Nos. 187-224http://www.jgid.org/currentissue.asp?sabs=n

[Reviewed earlier; No relevant content]

January 2013, Volume 39, Issue 1http://jme.bmj.com/content/current[Reviewed earlier]
http://www.idpjournal.com/contenthttp://www.ijidonline.com/http://jama.ama-assn.org/current.dtlhttp://www.emeraldinsight.com/journals.htm?issn=1477-7266&show=latesthttp://www.journals.uchicago.edu/toc/jid/currenthttp://www.jgid.org/currentissue.asp?sabs=nhttp://jme.bmj.com/content/currenthttp://www.idpjournal.com/contenthttp://www.ijidonline.com/http://jama.ama-assn.org/current.dtlhttp://www.emeraldinsight.com/journals.htm?issn=1477-7266&show=latesthttp://www.journals.uchicago.edu/toc/jid/currenthttp://www.jgid.org/currentissue.asp?sabs=nhttp://jme.bmj.com/content/current


16/28

January 2013; 62 (Pt 1)http://jmm.sgmjournals.org/content/current[Reviewed earlier; No relevant content]

Volume 1 Issue 4 December 2012http://jpids.oxfordjournals.org/content/current[Reviewed earlier]

Jan 05, 2013 Volume 381 Number 9860 p1 - 88http://www.thelancet.com/journals/lancet/issue/current

The LancetOn Dec 31, the world missed the deadline for the 24-year-old Global Polio Eradication

Initiative to halt all wild poliovirus transmission by the end of 2012. Set in 1988, WHO's originaltargetglobal eradication of polio by the year 2000has been extended several times. Withonly 215 cases reported worldwide as of Dec 26, 2012an encouraging contrast to 650 casesin 2011success seemed close.

But recently, the global effort to eradicate polio has suffered devastating setbacks. In mid-December, nine health workers were shot dead while travelling from house to house toadminister polio vaccine to children during the national anti-polio campaign in Pakistan. And onJan 1, six female Pakistani aid workers and a male doctor were shot dead. The brutal attackstook place in several locations, including Khyber Pakhtunkhwa province, which in 2012accounted for more than 40% of all Pakistan's polio cases and 46% of Pakistan's infected townsand districts; Karachi, the largest city in Pakistan with a population of 18 million; and Sindhprovince. The killing of the health workers was condemned as senseless and inexcusable byUN Secretary-General, Ban Ki-moon. Owing to the safety concerns, the UN was forced to haltits participation in the vaccination campaign, and the campaign itself has been suspendedtemporarily by the Government of Pakistan and the affected provinces.

In this tragedy, women and children are the main victims. Most of the health workers whowere killed were women, and the youngest was a schoolgirl aged 17 years. Female healthworkers are standing fearlessly and selflessly on the frontline of Pakistan's war against polio,because culturally only women are allowed to enter into houses to talk to mothers andvaccinate their children. Last June, in Federally Administered Tribal Areas, the Pakistani Taliban

banned polio vaccination in retaliation for the use of unmanned drones by the USA. It is of deepconcern that women who stand for something big have become the Pakistani Taliban's target.Female polio health workers are one example; the schoolgirl Malala Yousafzai, whom theTaliban shot in the head in October for campaigning for access to educationanother essentialingredient in promoting children's healthis another. More than 3.5 million Pakistani childrenhave missed vaccinations as a result of the campaign's suspension. Such attacks deprivePakistan's most vulnerable populationsespecially childrenof basic life-saving healthinterventions, said WHO and UNICEF in ajoint statement.
http://jmm.sgmjournals.org/content/currenthttp://jpids.oxfordjournals.org/content/currenthttp://www.thelancet.com/journals/lancet/issue/currenthttp://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspxhttp://www.polioeradication.org/tabid/461/iid/265/Default.aspxhttp://jmm.sgmjournals.org/content/currenthttp://jpids.oxfordjournals.org/content/currenthttp://www.thelancet.com/journals/lancet/issue/currenthttp://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspxhttp://www.polioeradication.org/tabid/461/iid/265/Default.aspx


17/28

The effect of the killing of polio vaccine workers in Pakistan will have repercussions for itsneighbour Afghanistan, which, together with Pakistan itself and Nigeria, is one of the remainingpolio-endemic countries. Genetic analysis shows that two of the three chains of poliotransmission in Afghanistan are from Pakistan. Other neighbouring countries have also been putat risk. For instance, polio broke out in China in 2011 for the first time since 1999 after beingimported from Pakistan; 18 people were paralysed and one died. Heidi Larson, ananthropologist who studies public trust in vaccines and immunisation at the London School ofHygiene and Tropical Medicine, pointed out that the killings of health workers in Pakistan couldbe a game changer in the global efforts to eradicate polio, calling for a rethink of deliverystrategies. She compared it with the 200304 immunisation boycott in northern Nigeria, led byreligious and political leaders, who claimed that the oral polio vaccine could cause sterility. Thisboycott led to poliovirus not only rebounding in Nigeria, but also spreading to 15 Africancountries and to Indonesia. The boycott and its effect prompted discussions between WHO, theOrganization of Islamic States, and local religious leaders to help address the rumours andcontain the further spread of polio. Indeed, the insecurity of and inaccessibility to vaccinationhave become the major impediments to the final push for polio eradication. Last year, KathleenO'Reilly and colleagues reported in The Lancet the effect of mass immunisation campaigns and

new oral poliovirus vaccines on the incidence of polio in Pakistan and Afghanistan. Theyreported that decreases in vaccination coverage in parts of Pakistan and southern Afghanistanhad severely restricted the effectiveness of bivalent oral poliovirus vaccines.

To eradicate polio, the work that the brave polio health workers died for must be continued in2013. Furthermore, it is imperative not only to ensure immunisation workers' security, but alsoto address the determinants behind the shooting of polio health workersie, to win the heartsof the public, to go beyond the polio only agenda, and to enhance polio vaccination'sintegration into the routine health and immunisation programme.

Jan 2013 Volume 13 Number 1 p1 - 96http://www.thelancet.com/journals/laninf/issue/current[Reviewed earlier]

NovemberDecember 2012; 32 (6)http://mdm.sagepub.com/content/current[Reviewed earlier]

A Multidisciplinary Journal of Population Health and Health PolicyDecember 2012 Volume 90, Issue 4 Pages 631807http://onlinelibrary.wiley.com/doi/10.1111/milq.2012.90.issue-4/issuetoc[Reviewed earlier]

Volume 493 Number 7430 pp5-128 3 January 2013
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60648-5/fulltexthttp://www.thelancet.com/journals/laninf/issue/currenthttp://mdm.sagepub.com/content/currenthttp://onlinelibrary.wiley.com/doi/10.1111/milq.2012.90.issue-4/issuetochttp://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60648-5/fulltexthttp://www.thelancet.com/journals/laninf/issue/currenthttp://mdm.sagepub.com/content/currenthttp://onlinelibrary.wiley.com/doi/10.1111/milq.2012.90.issue-4/issuetoc


18/28

http://www.nature.com/nature/current_issue.html[No relevant content]

January 2013, Volume 14 No 1 pp1-99http://www.nature.com/ni/journal/v14/n1/index.html[Reviewed earlier; No relevant content]

December 2012, Volume 18 No 12 pp1717-1857http://www.nature.com/nm/journal/v18/n12/index.html[Reviewed earlier]

January 2013 Vol 13 No 1http://www.nature.com/nri/journal/v13/n1/index.html[No relevant content]

January 3, 2013 Vol. 368 No. 1http://content.nejm.org/current.shtml

Donald R. Hopkins, M.D., M.P.H.N Engl J Med 2013; 368:54-63 January 3, 2013 DOI: 10.1056/NEJMra1200391Extract

Since the last case of naturally occurring smallpox, in 1977, there have been three majorinternational conferences devoted to the concept of disease eradication.1-3 Several otherdiseases have been considered as potential candidates for eradication,4 but the World HealthOrganization (WHO) has targeted only two other diseases for global eradication after smallpox.In 1986, WHO's policymaking body, the World Health Assembly, adopted the elimination ofdracunculiasis (guinea worm disease) as a global goal,5 and it declared the eradication ofpoliomyelitis a global goal in 1988.6 Although both diseases now appear to be close toeradication, the fact that neither goal has been achieved after more than two decades, andseveral years beyond the initial target dates for their eradication, underscores the dauntingchallenge of such efforts, as does the failure of previous attempts to eradicate malaria,

hookworm, yaws, and other diseases.1

Harvey V. Fineberg, M.D., Ph.D., and David J. Hunter, M.B., B.S., Sc.D., M.P.H.N Engl J Med 2013; 368:78-79January 3, 2013DOI: 10.1056/NEJMe1208801Extract

This issue of the Journal includes the first article in a series of review articles on globalhealth.1 In a journal that proudly bears the name of a U.S. domestic region, this series will
http://www.nature.com/nature/current_issue.htmlhttp://www.nature.com/ni/journal/v14/n1/index.htmlhttp://www.nature.com/nm/journal/v18/n12/index.htmlhttp://www.nature.com/nri/journal/v13/n1/index.htmlhttp://content.nejm.org/current.shtmlhttp://www.nejm.org/toc/nejm/368/1/http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref1http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref4http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref5http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref6http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref1http://www.nejm.org/toc/nejm/368/1/http://www.nejm.org/doi/full/10.1056/NEJMe1208801#ref1http://www.nature.com/nature/current_issue.htmlhttp://www.nature.com/ni/journal/v14/n1/index.htmlhttp://www.nature.com/nm/journal/v18/n12/index.htmlhttp://www.nature.com/nri/journal/v13/n1/index.htmlhttp://content.nejm.org/current.shtmlhttp://www.nejm.org/toc/nejm/368/1/http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref1http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref4http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref5http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref6http://www.nejm.org/doi/full/10.1056/NEJMra1200391#ref1http://www.nejm.org/toc/nejm/368/1/http://www.nejm.org/doi/full/10.1056/NEJMe1208801#ref1


19/28

show that local health and local health care are linked to sources of ill health elsewhere in theworld. Today, not only are health problems global, but lessons, insights, and fresh solutionsregarding such problems flow in all directions. The series is built around articles that explain theneed for global health, the challenges to achieving it, and the solutions to problems related toit

December 2012, 16(12)http://online.liebertpub.com/toc/omi/16/12[Reviewed earlier; No relevant content]

January 2013 - Volume 32 - Issue 1 pp: A13-A14,1-98,e1-e44http://journals.lww.com/pidj/pages/currenttoc.aspx

Desai, Rishi; Cortese, Margaret M.; Meltzer, Martin I.; Shankar, Manjunath; Tate, Jacqueline E.;Yen, Catherine; Patel, Manish M.; Parashar, Umesh D.Pediatric Infectious Disease Journal. 32(1):1-7, January 2013.doi: 10.1097/INF.0b013e318270362cAbstract:

Background: International data show a low-level increased risk of intussusception associatedwith rotavirus vaccination. Although US data have not documented a risk, we assumed a risksimilar to international settings and compared potential vaccine-associated intussusceptioncases with benefits of prevention of rotavirus gastroenteritis by a fully implemented USrotavirus vaccine program.Methods: To calculate excess intussusception cases, we used national data on vaccine coverageand baseline intussusception rates, and assumed a vaccine-associated intussusception relativerisk of 5.3 (95% confidence interval [CI]: 3.09.3) in the first week after the first vaccine dose,the risk seen in international settings. We used postlicensure vaccine effectiveness data tocalculate rotavirus disease burden averted.Results: For a US birth cohort of 4.3 million infants, vaccine-associated intussusception couldcause an excess 0.2 (range: 0.10.3) deaths, 45 (range: 2186) hospitalizations and 13 (range:625) cases managed in short-stay or emergency department settings. Vaccination would avert14 (95% CI: 1019) rotavirus-associated deaths, 53,444 (95% CI: 37,62272,882)hospitalizations and 169,949 (95% CI: 118,161238,630) emergency department visits.Summary benefitrisk ratios for death and hospitalization are 71:1 and 1093:1, respectively.

Conclusions: The burden of severe rotavirus disease averted due to vaccination compared withthe vaccine-associated intussusception events offers a side-by-side analysis of the benefits andpotential risks. If an intussusception risk similar to that seen internationally exists in the UnitedStates, it is substantially exceeded by the benefits of rotavirus disease burden averted byvaccination.
http://online.liebertpub.com/toc/omi/16/12http://journals.lww.com/pidj/pages/currenttoc.aspxhttp://online.liebertpub.com/toc/omi/16/12http://journals.lww.com/pidj/pages/currenttoc.aspxhttp://journals.lww.com/pidj/Fulltext/2013/01000/Potential_Intussusception_Risk_Versus_Benefits_of.2.aspxhttp://journals.lww.com/pidj/Fulltext/2013/01000/Potential_Intussusception_Risk_Versus_Benefits_of.2.aspxhttp://journals.lww.com/pidj/Abstract/2013/01000/Factors_Affecting_Human_Papillomavirus_Vaccine_Use.20.aspxhttp://journals.lww.com/pidj/Abstract/2013/01000/Factors_Affecting_Human_Papillomavirus_Vaccine_Use.20.aspx


20/28

Perkins, Rebecca B.; Apte, Gauri; Marquez, Cecilia; Porter, Courtney; Belizaire, Myrdell; Clark,Jack A.; Pierre-Joseph, NataliePediatric Infectious Disease Journal. 32(1):e38-e44, January 2013.doi: 10.1097/INF.0b013e31826f53e3Abstract:

Background: Although human papillomavirus (HPV) vaccination has been available for malessince 2009, its uptake remains low. In light of new recommendations for universal vaccinationof males, understanding parental attitudes toward this vaccine is important. This study aimed todescribe HPV-related knowledge and intention to accept HPV vaccination among White, Blackand Latino parents of sons and to assess vaccination rates among their sons.Methods: We interviewed parents (68 Black, 28 Latino and 24 White; mean age, 43.5) of sons(mean age, 14) attending an urban academic medical center and a community health center.Eligible parents self-identified as White, Black or Latino and spoke English, Spanish or Haitian-Creole. We collected demographic information, knowledge related to HPV vaccination, parentsintent to vaccinate sons and HPV vaccination rates. Descriptive statistics and multivariablelogistic regression were used to describe data.Results: Most parents were mothers, married, expressed a religious affiliation and had

completed high school or college. Parents had limited knowledge about HPV; White parentswere more knowledgeable than Black parents. Most parents (75%) intended to accept HPVvaccination if recommended by physicians; no racial differences were noted. However, only30% of sons were vaccinated. Logistic regression indicated that internet use was negativelyassociated with intention to vaccinate. Intention to vaccinate, clinical site of care and having anolder son were associated with vaccine receipt.Conclusions: Although parents in our study had limited understanding of HPV disease in males,most would vaccinate their sons if recommended by their physicians.

January 2013, VOLUME 131 / ISSUE 1http://pediatrics.aappublications.org/current.shtml

William J. Keenan, MDPediatrics 2013; 131:3-4[No abstract]Introductory CommentaryWhy would anyone, anywhere, question the importance of protective rights for children? Whywould anyone, anywhere, question the profound effect childrens rights have on communitywell-being? In this column, Dr Keenan describes the history and current status of childrensrights and challenges us to advocate for fuller implementation of those rights based on well-

established principles that are based in good public policy and science. Clearly, children do nothave the ability to make all the decisions affecting their optimal health and life success. Adultsmust decide how children are cared for and how we should vest authority and power to ensurethat every childs best possible outcome is achieved. Concerns should exist when policies andgovernmental structures become repressive and become exploitive. Children everywheredeserve to be treated as valued members in society and, when developmentally possible,participate in making life choices to their own benefit.

Jay E. Berkelhamer, MD, FAAP
http://pediatrics.aappublications.org/current.shtmlhttp://pediatrics.aappublications.org/current.shtml


21/28

December 1, 2012 - Volume 30 - Issue 12 pp: 1097-1214http://adisonline.com/pharmacoeconomics/pages/currenttoc.aspx[Reviewed earlier; No relevant content]

[Accessed 5 January 2013]http://www.plosone.org/

Odile Launay, Anne Krivine, Caroline Charlier, Van Truster, Vassilis Tsatsaris, Jacques Lepercq,Yves Ville, Carolyn Avenell, Thibaut Andrieu, Flore Rozenberg, Florence Artiguebielle, Jean-MarcTrluyer, Franois Goffinet, Inserm COFLUPREG Study GroupResearch Article | published 27 Dec 2012 | PLOS ONE 10.1371/journal.pone.0052303

AbstractBackgroundIn 2009, pregnant women were specifically targeted by a national vaccination campaign againstpandemic A/H1N1 influenza virus. The objectives of the COFLUPREG study, initially set up toassess the incidence of serious forms of A/H1N1 influenza, were to assess the consequences ofmaternal vaccination on pregnancy outcomes and maternal seroprotection at delivery.MethodsPregnant women, between 12 and 35 weeks of gestation, non vaccinated against A/H1N1 2009influenza were randomly selected to be included in a prospective cohort study conducted inthree maternity centers in Paris (France) during pandemic period. Blood samples were plannedto assess hemagglutination inhibition (HI) antibody against A/H1N1 2009 influenza at inclusionand at delivery.Results

Among the 877 pregnant women included in the study, 678 (77.3%) had serum samples bothat inclusion and delivery, and 320 (36.5%) received pandemic A/H1N1 2009 influenza vaccinewith a median interval between vaccination and delivery of 92 days (95% CI 48134). Atdelivery, the proportion of women with seroprotection (HI antibodies titers against A/H1N12009 influenza of 1:40 or greater) was 69.9% in vaccinated women. Of the 422 non-vaccinatedwomen with serological data, 11 (2.6%; 95%CI: 1.34.6) had laboratory documented A/H1N12009 influenza (1 with positive PCR and 10 with serological seroconversion). None of the 877studys women was hospitalized for flu. No difference on pregnancy outcomes was evidencedbetween vaccinated women, non-vaccinated women without seroconversion and non-vaccinated women with flu.

ConclusionDespite low vaccine coverage, incidence of pandemic flu was low in this cohort of pregnantwomen. No effect on pregnancy and delivery outcomes was evidenced after vaccination.

(Accessed 5 January 2013)http://www.plosmedicine.org/
http://adisonline.com/pharmacoeconomics/pages/currenttoc.aspxhttp://www.plosone.org/http://www.plosmedicine.org/http://adisonline.com/pharmacoeconomics/pages/currenttoc.aspxhttp://www.plosone.org/http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052303http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052303http://www.plosmedicine.org/


22/28

[No new relevant content]

December 2012http://www.plosntds.org/article/browseIssue.action

Florian Marks, Thi Thu Yen Nguyen, Nhu Duong Tran, Minh Hong Nguyen, Hai Ha Vu, ChristianG. Meyer, Young Ae You, Frank Konings, Wei Liu, Thomas F. Wierzba, Zhi-Yi XuBackgroundJapanese encephalitis (JE) is a flaviviral disease of public health concern in many parts of Asia.JE often occurs in large epidemics, has a high case-fatality ratio and, among survivors,frequently causes persistent neurological sequelae and mental disabilities. In 1997, the

Vietnamese government initiated immunization campaigns targeting all children aged 15 years.Three doses of a locally-produced, mouse brain-derived, inactivated JE vaccine (MBV) were

given. This study aims at evaluating the effectiveness of Viet Nam's MBV.Methodology

A matched case-control study was conducted in Northern Viet Nam. Cases were identifiedthrough an ongoing hospital-based surveillance. Each case was matched to four healthycontrols for age, gender, and neighborhood. The vaccination history was ascertained through JEimmunization logbooks maintained at local health centers.Principal FindingsThirty cases and 120 controls were enrolled. The effectiveness of the JE vaccine was 92.9%[95% CI: 66.698.5]. Confounding effects of other risk variables were not observed.ConclusionsOur results strongly suggest that the locally-produced JE-MBV given to 15 years old

Vietnamese children was efficacious.

(Accessed 5 January 2013)http://www.pnas.org/content/early/recent[No new relevant content]

Volume 5 Issue 3 November 2012

http://phe.oxfordjournals.org/content/current[Reviewed earlier]

Volume 19, Issue 1, Pages 1-70 (January 2013)http://www.sciencedirect.com/science/journal/14714914[No relevant content]
http://www.plosntds.org/article/browseIssue.actionhttp://www.pnas.org/content/early/recenthttp://phe.oxfordjournals.org/content/currenthttp://www.sciencedirect.com/science/journal/14714914http://www.plosntds.org/article/browseIssue.actionhttp://dx.plos.org/10.1371/journal.pntd.0001952http://dx.plos.org/10.1371/journal.pntd.0001952http://www.pnas.org/content/early/recenthttp://phe.oxfordjournals.org/content/currenthttp://www.sciencedirect.com/science/journal/14714914


23/28

4 January 2013 vol 339, issue 6115, pages 1-112http://www.sciencemag.org/current.dtl[No relevant content]

2 January 2013 vol 5, issue 166http://stm.sciencemag.org/content/current[No relevant content]

Volume 31, Issue 3, Pages 439-566 (7 January 2013)http://www.sciencedirect.com/science/journal/0264410X

Review ArticlePages 452-460Firdausi Qadri, Taufiqur Rahman Bhuiyan, David A. Sack, Ann-Mari SvennerholmAbstract

Oral mucosal vaccines have great promise for generating protective immunity against intestinalinfections for the benefit of large numbers of people especially young children. There howeverappears to be a caveat since these vaccines have to overcome the inbuilt resistance of mucosalsurfaces and secretions to inhibit antigen stimulation and responses. Unfortunately, thesevaccines are not equally immunogenic nor protective in different populations. When comparedto industrialized countries, children living in developing countries appear to have lowerresponses, but the reasons for these lowered responses are not clearly defined. The most likelyexplanations relate to undernutrition, micronutrient deficiencies, microbial overload on mucosalsurfaces, alteration of microbiome and microbolom and irreversible changes on the mucosa aswell as maternal antibodies in serum or breast milk may alter the mucosal pathology and lowerimmune responses to interventions using oral vaccines. The detrimental effect of adverseenvironment and malnutrition may bring about irreversible changes in the mucosa of childrenespecially in the first 1000 days of life from conception to after birth and up to two years ofage. This review aims to summarize the information available on lowered immune responses tomucosal vaccines and on interventions that may help address the constraints of these vaccineswhen they are used for children living under the greatest stress and under harmful adversecircumstances.

Original Research ArticlePages 480-486Kristina M. Bacon, Peter J. Hotez, Stephanie D. Kruchten, Shaden Kamhawi, Maria ElenaBottazzi, Jesus G. Valenzuela, Bruce Y. LeeAbstract
http://www.sciencemag.org/current.dtlhttp://stm.sciencemag.org/content/currenthttp://www.sciencedirect.com/science/journal/0264410Xhttp://www.sciencemag.org/current.dtlhttp://stm.sciencemag.org/content/currenthttp://www.sciencedirect.com/science/journal/0264410Xhttp://www.sciencedirect.com/science/article/pii/S0264410X12016052http://www.sciencedirect.com/science/article/pii/S0264410X12016052http://www.sciencedirect.com/science/article/pii/S0264410X12016258http://www.sciencedirect.com/science/article/pii/S0264410X12016258


24/28

Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneousleishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropicaldiseases in Latin America, especially in areas associated with human migration, conflict, andrecent deforestation. Because of the limitations of current chemotherapeutic approaches to CL,MCL, and DCL, several prototype vaccines are in different states of product and clinicaldevelopment. We constructed and utilized a Markov decision analytic computer model toevaluate the potential economic value of a preventative CL vaccine in seven countries in Latin

America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicatedthat even a vaccine with a relatively short duration of protection and modest efficacy could berecommended for use in targeted locations, as it could prevent a substantial number of cases atlow-cost and potentially even result in cost savings. If the population in the seven countrieswere vaccinated using a vaccine that provides at least 10 years of protection, an estimated41,000144,784 CL cases could be averted, each at a cost less than the cost of currentrecommended treatments. Further, even a vaccine providing as little as five years duration ofprotection with as little as 50% efficacy remains cost-effective compared with chemotherapy;additional scenarios resembling epidemic settings such as the one that occurred in Chaparral,Colombia in 2004 demonstrate important economic benefits.

Original Research ArticlePages 514-517Bonnie Paris, Tracey Arahood, Carl Asche, Gail AmundsonAbstract

ObjectiveIn 2009, voluntary public reporting of hospital health care personnel (HCP) vaccination ratesbegan in Illinois. We describe our experience over 3 influenza seasons and examine the impactuniversal policies have had on performance.Methods

A secure website was used to report monthly HCP vaccination rates by each participatinghospital. Overall and individual hospital performance was publicly reported each month.ResultsIn the first two seasons, there were 11 hospitals reporting with an average end of season rateof 76% (20092010) and 81% (20102011). In the 20112012 season, there were 22 hospitalsreporting, 9 of which had a new universal policy for HCP influenza vaccination. The average20112012 end of season rate was 72% for hospitals with a voluntary program and 95% forhospitals with a universal policy. HCP were also vaccinated earlier in the influenza season whena universal policy was in place, providing greater benefit over time.

Original Research Article

Pages 518-523Meral Akcay Ciblak, Grip PlatformuAbstractInfluenza infections cause considerable morbidity and mortality not only during the pandemicsbut also during annual epidemics. Vaccines are the most effective tools for preventing theinfection. Although World Health Organization (WHO) and Ministry of Health (MoH)recommends vaccination for people at increased risk, sales data indicate that vaccination rateremains low in Turkey. Vaccine recommended groups are well defined and reimbursed in
http://www.sciencedirect.com/science/article/pii/S0264410X12016180http://www.sciencedirect.com/science/article/pii/S0264410X12016180http://www.sciencedirect.com/science/article/pii/S0264410X12016155http://www.sciencedirect.com/science/article/pii/S0264410X12016155


25/28

Turkey. However, the prevalence of people in risk groups, current vaccination rates and factorsinfluencing vaccine uptake which are essential in order to develop and sustain effectivestrategies to increase vaccination rate are not documented. A thorough literature review wasperformed to determine the estimated number of people in risk groups, vaccination rates,factors influencing vaccine uptake in Turkey. Actions taken by the health authorities in order toincrease the vaccine uptake among specified risk groups are also summarized. Based on thepublished prevalence rates, current study calculated that there are approximately 27 to 33million people in risk groups. In addition, there are 428,000 health care providers serving in thepublic sector who are at increased risk for influenza infections. The lowest reported vaccinationrate (5.9%) was in the elderly 65 years of age and the highest (27.3%) in patients withCOPD. Finally, survey results indicated that leading factor negatively influencing vaccine uptakewas disbelief in the effectiveness of vaccine. In order to increase vaccination coverage, vaccinesare provided to health care providers free of charge and reimbursed for those in the riskgroups. Realizing the fact that combating flu requires multidisciplinary collaboration, astakeholder network, Grip Platformu, has been established in 2011 with the endorsement of theMoH to increase influenza awareness and vaccine coverage rates among risk groups inaccordance with WHO recommendations.

Original Research ArticlePages 533-537Hanqing He, En-fu Chen, Qian Li, Zhifang Wang, Rui Yan, Jian Fu, Jinren PanAbstract

The increasing proportions of adult cases were observed in the recent measles outbreaks inZhejiang Province, China. In order to identify the high-risk age groups of measles for targetedintervention, a seroprevalence survey of measles antibody was conducted among 1961participants aged 060 years randomly selected by age-stratified purpose sampling, and theeffect of revaccination program in secondary school was evaluated in Zhejiang Province. Theadjusted overall seropositivity rate of measles was 88% (95% confidence interval [CI]: 8689%) with geometric mean titers (GMT), 976 86 mIU/ml. The seropositivity rate of measleswas significantly lower in subjects aged 1519 years than aged 59 years (90% vs 96%,

2 = 5.21, p = 0.022). Both seropositivity rate and GMT level of measles were higher inparticipants aged 1014 years with 2 doses MCV than those with only 1 dose (95% vs 81%,1276 mIU/ml vs 666 mIU/ml). The seropositivity rate increased from 91% to 100% afterrevaccination with MCV among 184 secondary school students. The proportions of measlescases aged 15 years were reduced gradually (2 = 55.47, p = 0.000) from 2009 to 2011 afterimplementing the revaccination campaign on secondary school students since 2008. Ourfindings strongly suggested that a revaccination opportunity with MCV for adolescents helps toimprove the population immunity, and it can be conducted effectively and practically insecondary school students.

(Accessed 5 January 2013)http://www.dovepress.com/vaccine-development-and-therapy-journal[No new relevant content]
http://www.dovepress.com/vaccine-development-and-therapy-journalhttp://www.sciencedirect.com/science/article/pii/S0264410X12016076http://www.sciencedirect.com/science/article/pii/S0264410X12016076http://www.dovepress.com/vaccine-development-and-therapy-journal


26/28

Vol 15 | No. 8 | December 2012 | Pages 991-1192http://www.valueinhealthjournal.com/current[Reviewed earlier]

No new content.

Beginning in June 2012, Vaccines: The Week in Reviewexpanded to alert readers tosubstantive news, analysis and opinion from the general media on vaccines, immunization,global; public health and related themes. Media Watchis not intended to be exhaustive, butindicative of themes and issues CVEP is actively tracking. This section will grow from an initialbase of newspapers, magazines and blog sources, and is segregated from Journal Watchabove

which scans the peer-reviewed journal ecology.We acknowledge the Western/Northern bias in this initial selection of titles and invite

suggestions for expanded coverage. WE are conservative in our outlook of adding news sourceswhich largely report on primary content we are already covering above. Many electronic mediasources have tiered, fee-based subscription models for access. We will provide full-text wherecontent is published without restriction, but most publications require registration and somesubscription level.

http://www.bbc.co.uk/Accessed 5 January 2013

[No new, unique, relevant content]

http://www.economist.com/Accessed 5 January 2013


http://www.ft.comAccessed 5 January 2013

[No new unique, relevant content]

http://www.forbes.com/Accessed 5 January 2013


http://www.foreignaffairs.com/November/December 2012 Volume 91, Number 6
http://www.valueinhealthjournal.com/currenthttp://www.bbc.co.uk/http://www.economist.com/http://www.ft.com/http://www.forbes.com/http://www.foreignaffairs.com/articles/137312/laurie-garrett/money-or-die?page=4http://www.valueinhealthjournal.com/currenthttp://www.bbc.co.uk/http://www.economist.com/http://www.ft.com/http://www.forbes.com/http://www.foreignaffairs.com/articles/137312/laurie-garrett/money-or-die?page=4


27/28

Accessed 5 January 2013


http://www.foreignpolicy.com/Accessed 5 January 2013]


http://www.guardiannews.com/Accessed 5 January 2013


http://www.huffingtonpost.com/Accessed 5 January 2013[No new, unique, relevant content]

http://www.newyorker.com/Accessed 5 January 2013


Accessed 5 January 2013


http://www.nytimes.com/Accessed 5 January 2013.[No new, unique, relevant content]

http://www.reuters.com/Accessed 5 January 2013[No new, unique, relevant content]

http://online.wsj.com/home-page

Accessed 5 January 2013[No new, unique, relevant content]

http://www.washingtonpost.com/Accessed 5 January 2013[No new, unique, relevant content]
http://www.foreignpolicy.com/http://www.guardiannews.com/http://www.huffingtonpost.com/http://www.newyorker.com/http://www.nytimes.com/http://www.reuters.com/http://online.wsj.com/home-pagehttp://www.washingtonpost.com/http://www.foreignpolicy.com/http://www.guardiannews.com/http://www.huffingtonpost.com/http://www.newyorker.com/http://www.npr.org/blogs/health/133188449/public-healthhttp://www.nytimes.com/http://www.reuters.com/http://online.wsj.com/home-pagehttp://www.washingtonpost.com/


28/28

Items of interest from a variety of twitter feeds associated with immunization, vaccines andglobal public health. This capture is highly selective and is by no means intended to beexhaustive.

Twitter Watch will resume next week.

* * * *

is a service of the Center for Vaccines Ethics and Policy (CVEP) which issolely responsible for its content. Support for this service is provided by its governing institutions

Department of Medical Ethics, NYU Medical School;The Wistar Institute Vaccine Centerand theChildrens Hospital of Philadelphia Vaccine Education Center. Additional support is provided byPATHVaccine Development Programand theInternational Vaccine Institute(IVI), and by vaccine industryleaders including GSK, Merck, Pfizer, and sanofi pasteur (list in formation), as well as the DevelopingCountries Vaccine Manufacturers Network (DCVMN). Support is also provided by a growing list ofindividuals who use this service to support their roles in public health, clinical practice, government,

NGOs and other international institutions, academia and research organizations, and industry.

* * * *
http://centerforvaccineethicsandpolicy.wordpress.com/http://pophealth.med.nyu.edu/divisions/medical-ethicshttp://www.wistar.org/vaccinecenter/default.htmlhttp://www.chop.edu/service/vaccine-education-center/home.htmlhttp://sites.path.org/vaccinedevelopment/http://sites.path.org/vaccinedevelopment/http://sites.path.org/vaccinedevelopment/http://www.ivi.org/http://www.dcvmn.org/index.aspxhttp://centerforvaccineethicsandpolicy.wordpress.com/http://pophealth.med.nyu.edu/divisions/medical-ethicshttp://pophealth.med.nyu.edu/divisions/medical-ethicshttp://www.wistar.org/vaccinecenter/default.htmlhttp://www.chop.edu/service/vaccine-education-center/home.htmlhttp://sites.path.org/vaccinedevelopment/http://sites.path.org/vaccinedevelopment/http://www.ivi.org/http://www.dcvmn.org/index.aspx

vaccines_the week in review_5 january 2013

Documents